Libby Echo:Prio vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Libby Echo:Prio

by Dyad Medical

Tempus ECG-AF

by Tempus AI, Inc.

AI Verdict

Tool A, Libby Echo:Prio, is designed for comprehensive echocardiogram analysis, offering automated cardiac measurements and decision support for general cardiac function. In contrast, Tool B, Tempus ECG-AF, focuses specifically on analyzing 12-lead ECGs to identify the risk of new-onset atrial fibrillation in patients aged 65 or older. Therefore, while both are cardiology AI tools, they address different diagnostic needs using distinct imaging modalities.

Choose Libby Echo:Prio if…

Choose Libby Echo:Prio if your clinical setting requires rapid, consistent, and AI-powered analysis of echocardiograms to support immediate diagnostic and treatment decisions. This tool is ideal for cardiologists and critical care specialists seeking automated cardiac measurements and a reliable second opinion to enhance efficiency and reduce variability in cardiac function quantification.

View Libby Echo:Prio →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your objective is to proactively identify elderly patients (65+) at elevated risk of developing new-onset atrial fibrillation or flutter within the next year. This solution is best suited for integrating into primary care or cardiology workflows to enable earlier follow-up and preventative strategies for at-risk individuals based on their 12-lead ECGs.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Libby Echo:Prio	Tempus ECG-AF
Pricing	Custom	Contact vendor
Deployment	Cloud-based	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available	No AI-estimated	Yes AI-estimated
FDA Status	Yes AI-estimated	Yes AI-estimated
HIPAA	No AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Libby Echo:Prio

Libby Echo:Prio (Tool A) is a cloud-based platform offering remote access from any device and is designed to be embedded in existing clinical workflows, suggesting high flexibility and ease of access. Tempus ECG-AF (Tool B) is a software solution integrated into facility systems, which, while integrated, may not offer the same level of remote accessibility as a cloud-native platform.

Clinical Value

Tempus ECG-AF

Tempus ECG-AF (Tool B) offers significant clinical value by identifying patients at increased risk of developing Atrial Fibrillation within 12 months, enabling earlier identification and proactive follow-up for a specific high-impact condition. While Libby Echo:Prio (Tool A) provides valuable decision support and automated measurements for echocardiograms, Tool B's predictive capability for future risk offers a distinct advantage in preventative care and patient management.

Pricing & Value

Tempus ECG-AF

Tempus ECG-AF (Tool B) clearly outlines CMS reimbursement availability with specific CPT codes and a Medicare rate, providing transparency and a clear path to financial viability for healthcare providers. Libby Echo:Prio (Tool A) only states 'custom' pricing and requires contacting the vendor, offering no public transparency regarding its cost or potential for reimbursement.

Enterprise Readiness

Tempus ECG-AF

Tempus ECG-AF (Tool B) explicitly states it is HIPAA compliant and has a Business Associate Agreement (BAA), which are fundamental requirements for enterprise adoption in healthcare. Libby Echo:Prio (Tool A) states it is neither HIPAA compliant nor has a BAA, posing significant barriers for deployment within regulated healthcare environments.

Innovation

Tempus ECG-AF

Both tools leverage AI in cardiology, but Tempus ECG-AF (Tool B) demonstrates a higher degree of innovation through its predictive analytics for identifying future AF risk from standard ECGs, trained on a massive dataset. Libby Echo:Prio (Tool A) focuses on automating and standardizing existing echocardiogram analysis, which is valuable but less novel than predicting future disease onset.

Support & Docs

Tie

Neither the provided structured facts nor readily available public information from web searches offer specific details regarding the level of support or documentation provided for either Libby Echo:Prio (Tool A) or Tempus ECG-AF (Tool B). Therefore, it is not possible to distinguish between the two on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Libby Echo:Prio	Tempus ECG-AF
Name	Libby Echo:Prio	Tempus ECG-AF
Company	Dyad Medical	Tempus AI, Inc.
Description	FDA-cleared, cloud-based AI platform for fast, data-driven echocardiogram analysis, providing decision support and automated cardiac measurements for clinicians.	FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up.
Primary Analysis Target	Echocardiogram analysis for cardiac function quantification	12-lead ECG analysis for Atrial Fibrillation/flutter (AF) risk
Target Patient Population	Not specified	Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery

Videos

Demos, reviews, and walkthroughs featuring Libby Echo:Prio and Tempus ECG-AF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What specific cardiac data does each tool analyze?

Libby Echo:Prio by Dyad Medical is designed for fast, data-driven echocardiogram analysis, providing automated cardiac measurements and decision support for clinicians. Tempus ECG-AF, on the other hand, is an AI-based algorithm that analyzes 12-lead ECG recordings.

For which patient populations are these tools primarily intended?

Libby Echo:Prio offers general decision support and automated measurements for echocardiogram analysis. Tempus ECG-AF is specifically intended for patients aged 65 or older without pre-existing atrial fibrillation/flutter (AF), pacemakers, ICDs, or recent cardiac surgery, to identify their risk of developing new-onset AF within 12 months.

What are the financial implications and reimbursement options for each tool?

Libby Echo:Prio has custom pricing, requiring direct vendor contact for details. Tempus ECG-AF has CMS reimbursement available, with specific CPT codes (0764T and 0765T) and a Medicare rate of $128.90, effective January 1, 2025.

What is the primary clinical goal or outcome each tool aims to achieve?

Libby Echo:Prio aims to provide fast, data-driven echocardiogram analysis, decision-making support for cardiac function quantification, and automated estimation of cardiac measurements. Tempus ECG-AF's goal is to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter within the next 12 months, supporting earlier identification and follow-up.

Are there any specific compatibility requirements for using these tools?

Libby Echo:Prio is a cloud-based platform for remote access from any device, suggesting broad compatibility with echocardiogram images. Tempus ECG-AF is compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems.